A Semax protocol, in the sense a research paper uses the word, is a specification: which organism, which route, how much, on what schedule, and above all which outcome was measured. Set out that way, the record is easy to summarise and easy to check against what people claim about it.
The vendor we point lifters to
Semax from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
The published certificate for batch 30-05260628 carries a kinetic chromogenic LAL endotoxin test to USP Chapter 85, reporting under 0.20 EU/mL against a 0.5 EU/mL limit, plus a sterility screen. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 21, 2026.
| Protocol family | Organism | Route | What was measured | Relevance to body composition |
|---|---|---|---|---|
| Russian clinical use | Human | Nasal | Neurological and cognitive outcomes | None measured |
| Neuroprotection models | Rat | Varies by study | Tissue damage under an experimental insult | None measured |
| Neurochemistry and gene expression | Rat | Varies by study | Neurotrophic factor expression in brain tissue | None measured |
| Registered Western trials | None exist | Not applicable | Nothing | Nothing |
| Vendor and forum protocols | Human, uncontrolled | Nasal or injection | Nothing recorded systematically | Nothing |
The right hand column is the same the whole way down, and it is the finding of this article.
What a Semax protocol actually specifies in the record
Two of those five rows are research. The Russian clinical work sits inside a medicines system, with patients, indications and a manufactured pharmaceutical product. The animal work sits in neuroscience laboratories, with rats, injury models and tissue measurements.
The two are not versions of each other. A rat neuroprotection model asks whether damage is reduced after a controlled insult. A clinical course asks whether a patient's symptoms improve. They use different endpoints because they are answering different questions, and neither question involves a muscle.
The third row that people treat as research, the vendor protocol, is not a protocol at all. It has an amount and sometimes a duration, and it has no defined outcome, no comparison group and no measurement. A specification without an endpoint cannot succeed or fail, which is precisely why it never does.
Two protocol families, and the gap between them
The gap between the clinical and the animal work is where most confusion lives.
Animal protocols are readable. A published rat study states the model, the route, the schedule and the measurement, and another laboratory could in principle repeat it. What limits those studies is not transparency, it is species: a rat brain protected in an injury model tells you about rats in injury models.
The Russian clinical protocols are the opposite. They concern the organism a reader cares about, humans, and they exist inside a regulatory and publishing system that a reader outside it cannot inspect. You cannot pull the review, examine how outcomes were defined, or see the studies that were run and not published.
So one family is checkable but in the wrong species, and the other is in the right species but not checkable from here. That is the structural problem with this compound, and no amount of reading vendor pages resolves it.
The vendor protocol, and what it borrows
Look closely at a supplier's suggested protocol and you can usually see its parts.
The amount is generally lifted from Russian clinical practice, which means it was chosen for a patient with an indication, using a manufactured nasal medicine. The route is often changed to injection, because that is what a vial of powder implies, and the change is made silently. The duration is invented or copied. The purpose, improved focus or faster progress in the gym, corresponds to nothing in either source.
What emerges looks like a protocol because it has the furniture of one. It has no study behind it, and its most important component, the outcome it is meant to produce, has never been measured in any organism.
Why an injury model cannot answer a healthy person's question
The rat neuroprotection designs are worth understanding properly, because they are the source of most of the impressive language attached to this compound.
In a study of that kind an animal is subjected to a controlled insult, something like restricted blood flow or a chemical exposure, and the question is whether treatment limits the resulting damage. The design is built to detect protection against a specific harm, on a short timescale, in tissue that has been deliberately injured.
That design cannot tell you what happens in an uninjured animal, because an uninjured animal has no damage to limit. It cannot tell you about function months later, because it does not run that long. And it cannot tell you anything about a healthy human, because the model exists precisely to create an abnormal state that healthy humans are not in.
None of this is a criticism of the studies. They answer the question they were built to answer. The error is downstream, where protection against experimental injury in rats becomes a general claim about slowing decline in people, and then, on a body composition site, a claim about ageing muscle. Neither step was tested by the design that started it.
The measurement that no protocol in this literature included
This is the shortest section and the one that matters most here. Across the clinical use, the rodent neuroprotection work and the neurochemical studies, no protocol measured muscle mass, fibre size, strength, power, muscle protein synthesis or body fat. Not as a primary outcome, not as a secondary one, not as an incidental observation.
That is why no protocol on this page can be adapted for a body composition goal. Adapting a protocol means changing the amount or the schedule while keeping the endpoint. Here there is no endpoint to keep.
The protocol a lifter is actually running
Set aside the published record for a moment and look at what someone reading this page would really be doing.
They would be taking an unverified compound, at an amount copied from a medical system they cannot audit, possibly by a route that system does not use, for a duration nobody established, while also training, sleeping variably, eating variably and hoping to notice a difference in a body that changes slowly for a dozen other reasons.
That is a single subject experiment with no control condition, no blinding, no baseline measurement and an outcome assessed by the person who paid for the compound. It is not a bad protocol so much as a design incapable of producing a result. Whatever happens over the following months, it will not be attributable, and it will feel attributable, which is the trap.
The one thing that improves it is measurement taken before anything starts: body weight trend, a real body composition measure, load lifted on a few fixed movements, sessions completed, sleep. Those do not turn it into evidence. They at least mean the person is comparing something against something, rather than comparing a memory against a photograph.
Reading the protocol record, question by question
Is there a published human protocol for Semax?
There is documented clinical use inside Russia with amounts and durations attached to medical indications. There is no published Western protocol, and no registered Western trial to produce one.
Can a rat protocol be adapted to a person?
No. Route, clearance and target tissue differ between species, and the rat endpoints were brain measurements. Scaling the number would still leave you with a design that measures nothing you want to know.
Does a supplier's suggested protocol count as evidence?
No. It has no outcome, no control group and no measurement, so it cannot produce a result of any kind.
Why does the same protocol appear on many sites?
Because pages copy each other. Repetition of a figure is a fact about publishing, not about pharmacology.
Did any protocol combine it with a training programme?
None. Exercise has never appeared in a study design for this compound in any organism.
What a protocol worth this site's attention would look like
It is worth stating the standard, so that any future claim can be measured against it rather than argued about.
It would recruit healthy adults who train, not patients with a neurological diagnosis, because the population determines whether a result transfers. It would include a placebo group and blind both the participants and the assessors, since the outcomes people report here are exactly the ones expectation moves most. It would run long enough for a training adaptation to appear, which means months rather than weeks. It would specify the route and use a product of verified identity and content. And it would name body composition and performance as endpoints in advance: lean mass by a real measurement, load lifted, sessions completed.
Nothing resembling that has been run for this compound anywhere. Until it is, the protocol question for a lifter has an unusual answer. There is no protocol to follow because there is no result to reproduce.